Neiger Reto, Witt Angela L, Noble Ann, German Alexander J
Department of Veterinary Clinical Sciences, Royal Veterinary College, London, UK.
J Vet Intern Med. 2004 Mar-Apr;18(2):160-4. doi: 10.1892/0891-6640(2004)18<160:ttftop>2.0.co;2.
Hyperadrenocorticism is a rare syndrome in cats. Current medical therapy is unsatisfactory and prognosis for long-term survival with surgical treatment is guarded. We report on 5 cats treated with the 3-beta hydroxysteroid dehydrogenase inhibitor trilostane. Diagnosis was confirmed in all cats by endocrine testing. Three cats had concurrent diabetes mellitus. Trilostane reduced clinical signs and improved endocrine test results in all cats, but insulin requirements did not change and all continued to have some signs of hypercortisolemia. Two died or were euthanized after 16 and 140 days, whereas 3 were still alive 6, 11, and 20 months after the start of trilostane therapy. Trilostane ameliorates clinical signs of feline hyperadrenocorticism, but more research is needed before it can be recommended for treatment.
肾上腺皮质功能亢进在猫中是一种罕见的综合征。目前的药物治疗效果不理想，手术治疗的长期生存预后也不容乐观。我们报告了5只接受3-β羟类固醇脱氢酶抑制剂曲洛司坦治疗的猫。所有猫均通过内分泌检测确诊。3只猫同时患有糖尿病。曲洛司坦减轻了所有猫的临床症状并改善了内分泌检测结果，但胰岛素需求量没有变化，所有猫仍有一些高皮质醇血症的迹象。2只猫在16天和140天后死亡或被安乐死，而3只猫在曲洛司坦治疗开始后的6、11和20个月仍存活。曲洛司坦可改善猫肾上腺皮质功能亢进的临床症状，但在推荐用于治疗之前还需要更多的研究。
